Built on Over 25 Years of Experience Treating Acute Lymphoblastic Leukemia (ALL)1

ONCASPAR-Containing Regimens Help Make Remission Possible

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with first-line ALL or ALL and hypersensitivity to native forms of L-asparaginase.1

ONCASPAR is available for ALL regimens in patients aged ≥22 years.1

Reaching remission helps adolescent and young adult (AYA) and adult patients look to their future

Asparaginase-containing regimens have long been the standard of care and guidelines recommend asparaginase in young adult patients with ALL when used as part of a multi-agent chemotherapeutic regimen.2,3

Pegaspargase-containing regimens are recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for your AYA patients with ALL.2,3,*

*The ALL Panel considers AYAs to be between the ages of 15 and 39 years. However, this age range is not a firm reference point because some of the recommended regimens have not been comprehensively tested across all ages.3

Abbreviation: NCCN, National Comprehensive Cancer Network® (NCCN®).

Discover ONCASPAR for the treatment of ALL

ONCASPAR Molecule

About ONCASPAR

Explore More
Shield icon

Efficacy & Safety

See The Data
Treatment Information

ALL and Treatment in AYAs

Learn More
IV bag

Dosing & Monitoring

Learn More

Contact a representative

If you have questions or would like to learn more about ONCASPAR, let us know and a representative will get in touch

CONTACT US
A doctor speaks with a Servier representative.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION Section

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR (pegaspargase) or to any of the excipients.
  • History of serious thrombosis with prior L-asparaginase therapy.
  • History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy.
  • History of serious hemorrhagic events with prior L-asparaginase therapy.
  • Severe hepatic impairment.

WARNINGS and PRECAUTIONS 

Anaphylaxis and Serious Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur. The risk of serious hypersensitivity reactions is higher in patients with known hypersensitivity to (E.) coli derived L-asparaginase formulations. Premedicate patients 30-60 minutes prior to administration of ONCASPAR. Observe patients for 1 hour after administration in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis. Discontinue ONCASPAR in patients with serious hypersensitivity reactions.

Thrombosis: Serious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue ONCASPAR in patients with serious thrombotic events.

Pancreatitis: Pancreatitis can occur. Fatal outcomes have been reported. Inform patients of the signs and symptoms of pancreatitis, which, if left untreated, could be fatal. Discontinue ONCASPAR in patients where pancreatitis is suspected. If pancreatitis is confirmed, do not resume ONCASPAR. 

Glucose Intolerance: Glucose intolerance can occur and, in some cases, be irreversible. Monitor serum glucose. 

Hemorrhage: Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur. Evaluate patients with signs and symptoms of hemorrhage with coagulation parameters including PT, PTT, and fibrinogen. Consider appropriate replacement therapy in patients with severe or symptomatic coagulopathy. Discontinue ONCASPAR for severe or life-threatening hemorrhage. 

Hepatotoxicity: Hepatotoxicity and abnormal liver function can occur. Evaluate bilirubin and transaminases at least weekly during cycles of treatment through at least 6 weeks after the last dose. In the event of serious liver toxicity, discontinue ONCASPAR and provide supportive care.

ADVERSE REACTIONS

The most common grade 3 and 4 adverse reactions with ONCASPAR (>5%) included hypoalbuminemia, elevated transaminase, febrile neutropenia, hypertriglyceridemia, hyperglycemia, bilirubin increased, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, and infections. 

INDICATIONS AND USAGE

ONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with:

  • First-line acute lymphoblastic leukemia (ALL)
  • ALL and hypersensitivity to native forms of L-asparaginase
Please see Full Prescribing Information.